NRX Pharmaceuticals, Inc. — FY2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. The company became Nasdaq-listed through the May 24, 2021 reverse recapitalization with Big Rock Partners Acquisition Corp. NRx is a clinical-stage pharmaceutical company with no approved commercial products or product revenue.
Business context
- Primary programs are NRX-100/NRX-101, a sequential ketamine followed by D-cycloserine/lurasidone regimen for bipolar depression with suicidal ideation, and ZYESAMI (aviptadil) for COVID-19-related respiratory failure and potentially other pulmonary diseases.
- NRX-101 has FDA Fast Track, Breakthrough Therapy, Biomarker Letter of Support, and Special Protocol Agreement designations. ZYESAMI has FDA Fast Track designation.
- The company discontinued the BriLife vaccine project in March 2022 and is prioritizing U.S.-focused development of ZYESAMI and NRX-101.
Financial performance and liquidity
| Metric | 2021 | 2020 | Change or comment |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue since inception |
| Research and development expense | $20.3 million | $10.6 million | Increase primarily from ZYESAMI clinical development |
| General and administrative expense | $74.9 million | $11.4 million | Includes substantial stock-based and consulting expense |
| Total operating expenses | $115.8 million | $51.4 million | Increase of $64.4 million |
| Net loss | $93.1 million | $51.8 million | Loss increased by $41.3 million |
| Net loss per share | $1.98 | $1.51 | Basic and diluted, before deemed dividends |
| Net loss attributable to common stockholders | $348.9 million | $51.8 million | Includes $253.1 million deemed dividend for contingent earnout shares and $2.7 million deemed dividend related to warrants |
| Cash at December 31 | $27.6 million | $1.9 million | Improved through financing and merger proceeds |
| Net cash used in operating activities | $37.7 million | $2.3 million | Significantly higher cash burn |
| Net cash provided by financing activities | $63.5 million | $3.2 million | Included private placements, warrant exercises, and merger/PIPE proceeds |
| Total assets | $32.7 million | $2.9 million | |
| Total liabilities | $11.9 million | $46.7 million | Declined mainly due to settlement-liability reclassification and debt reduction |
| Stockholders’ equity | $20.8 million | $(43.8) million | Improved following the public listing and equity financings |
Margins are not meaningful because the company generated no revenue. The filing reports $518,000 of current notes payable and accrued interest at year-end, primarily a $500,000 Relief Therapeutics loan. No significant long-term debt was outstanding. Management stated that cash, together with the February 2022 financing, should fund planned operations for at least 12 months after issuance of the financial statements, but acknowledged the need for additional capital and the risk that financing may not be available on acceptable terms.
Material changes versus the prior period
- Operating expenses more than doubled, driven by higher clinical and regulatory spending, public-company costs, stock-based compensation, consulting costs, and legal and professional fees.
- General and administrative expense included approximately $56.0 million of consultant fees, including approximately $41.0 million fair value for 4.0 million shares issued in connection with the BriLife-related Shareholder Agreement.
- Non-cash consulting expense was approximately $53.8 million, while non-cash settlement expense related to the GEM warrant was $21.4 million.
- The May 2021 merger and related financings increased cash and equity, but also created contingent earnout obligations. The year-end Earnout Cash liability was $4.6 million, down from an initial fair value of $25.5 million.
- Shares outstanding increased from 43.0 million at December 31, 2020 to 58.8 million at December 31, 2021; 66.6 million shares were outstanding as of March 24, 2022.
- In February 2022, the company raised approximately $25.0 million gross through a private placement of 7.8 million shares and accompanying investment options.
Clinical, regulatory and outlook items
- ZYESAMI: The 196-patient Phase IIb/III intravenous trial did not meet its primary endpoint across all sites without adjustment for prespecified factors, but reported statistically significant survival results and favorable adjusted or subgroup analyses. The FDA denied the initial EUA request in November 2021 because of insufficient benefit and risk data. A narrower EUA request for patients at risk of death despite remdesivir and other approved therapies was pending as of the filing date.
- ZYESAMI remained in the NIH ACTIV-3b/TESICO Phase III trial, which had enrolled approximately 465 of a planned 640 participants as of March 15, 2022. Management expected a potential readout in the second half of 2022 and was evaluating EUA, accelerated approval, and traditional NDA pathways.
- The I-SPY inhaled ZYESAMI study was stopped for futility after approximately 52 patients. The AVICOVID-2 inhaled study was paused while the company evaluated safety, feasibility, sample size, and endpoint changes.
- NRX-101: The prior Phase IIb/III program was paused during the pandemic. The company planned to restart a registrational study using commercial-level material in the second half of 2022 and expected, if successful, to submit an NDA in 2023. A separate Phase II study in bipolar depression with sub-acute suicidal ideation was being initiated.
- Manufacturing remains a significant execution issue. ZYESAMI formulation work demonstrated approximately 150–180 days of refrigerated stability, but the company had not yet scaled production to its targeted 500-liter batch size. Polypeptide-supplied API had not yet been qualified by the FDA for human use.
- Management does not provide conventional financial revenue or earnings guidance. Outlook is dependent on regulatory approvals, clinical outcomes, manufacturing scale-up, capital availability, and evolving COVID-19 treatment demand.
Risks, contingencies and unusual items
- The company has a limited operating history, recurring losses, negative operating cash flow, no product revenue, and expects additional financing requirements.
- Relief Therapeutics sued NRx in October 2021 over the aviptadil collaboration and alleged funding and contractual obligations. NRx filed counterclaims seeking at least $185 million. Mediation began in February 2022; the outcome remains uncertain.
- A federal securities class action was filed in January 2022 alleging that the company made misleading disclosures concerning the sufficiency of ZYESAMI’s EUA data. The company stated that the claims are without merit and had not been served as of the filing.
- Management identified a material weakness in internal control over financial reporting related to lack of segregation of duties in preparing and approving disclosures. Disclosure controls were therefore deemed ineffective as of December 31, 2021; remediation includes establishing a Disclosure Committee.
- ZYESAMI’s principal formulation was protected by pending, not issued, patent applications at the filing date, creating potential future generic competition if regulatory data or other exclusivity is insufficient.
- NRX-100 uses ketamine, a Schedule III controlled substance, creating DEA, supply, quota, security, and abuse-liability risks.
- The filing contains an inconsistency: the audited financial statements and MD&A report a 2021 net loss of $93.1 million, while one risk-factor passage refers to a $113.5 million 2021 loss. The audited financial statements should be treated as the primary reported figure unless clarified by the company.
Investor verification checklist
- Verify the status and outcome of the narrower ZYESAMI EUA request, the ACTIV-3b/TESICO trial, and any planned accelerated-approval or NDA submissions.
- Assess whether the company’s cash balance and February 2022 financing are sufficient relative to projected clinical, manufacturing, legal, and public-company cash needs.
- Review dilution from the February 2022 financing, outstanding warrants and options, potential earnout shares, and other contingent equity instruments.
- Monitor the Relief Therapeutics litigation, NRx’s $185 million counterclaim, and the securities class action for potential cash or operational consequences.
- Confirm remediation of the material weakness and whether subsequent filings report effective disclosure and internal controls.
- Evaluate the commercial and patent protection of ZYESAMI, including FDA qualification of API, manufacturing scale-up, stability, and the status of pending formulation patents.
- Reconcile the reported 2021 net-loss discrepancy and review the related non-cash deemed dividends and fair-value adjustments.